These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11569989)

  • 41. Side effects and combination anti-HIV drugs.
    Treat Rev; 1997 Nov; (No 26-27):14-5. PubMed ID: 11364933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Changes in lipid metabolism of patients infected by human immunodeficiency virus. A pathogenic hypothesis].
    Rodríguez Vidigal FF; Muñoz Sanz A
    Med Clin (Barc); 2000 Jun; 115(4):145-50. PubMed ID: 10996887
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug reactions & lipodystrophy workshop.
    Coppedge B
    STEP Perspect; 1999; 99(3):17-8. PubMed ID: 11366865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of zidovudine in development of lipoatrophy.
    Moyle GJ
    AIDS Read; 2005 Nov; 15(11):591-4, 599-600, 603. PubMed ID: 16329181
    [No Abstract]   [Full Text] [Related]  

  • 46. Gynecomastia and HAART.
    Post JJ
    AIDS Read; 2000 May; 10(5):314. PubMed ID: 10851722
    [No Abstract]   [Full Text] [Related]  

  • 47. ["Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors].
    Milpied-Homsi B; Krempf M; Gueglio B; Raffi F; Stalder JF
    Ann Dermatol Venereol; 1999 Mar; 126(3):254-6. PubMed ID: 10394440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complications and side effects. Minimizing fat loss--comparing nukes.
    TreatmentUpdate; 2007; 19(5):6. PubMed ID: 17955615
    [No Abstract]   [Full Text] [Related]  

  • 49. Simplifying suppression: switching therapies to improve HIV disease management.
    Moyle GJ
    AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867
    [No Abstract]   [Full Text] [Related]  

  • 50. HAART attack: metabolic disorders during long-term antiretroviral therapy.
    David E
    BETA; 1999 Apr; 12(2):10-4. PubMed ID: 11366674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching meds: from protease inhibitors to non-nukes.
    TreatmentUpdate; 2001; 12(10):1-2. PubMed ID: 11570061
    [No Abstract]   [Full Text] [Related]  

  • 52. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 53. Three HIV-treating physicians express their professional opinions regarding a case scenario.
    Gathe JC; Stone VE; Lahart C
    Res Initiat Treat Action; 2000 Sep; 6(3):23-5. PubMed ID: 11708163
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Damage to the power plant.
    TreatmentUpdate; 2002 Mar; 14(3):1-2. PubMed ID: 12033185
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeting a deadly scrap of genetic code.
    Cowley G
    Newsweek; 1996 Dec; 128(23):68-9. PubMed ID: 10162944
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard dosing schedule for anti-HIV drugs.
    Proj Inf Perspect; 1998 Dec; (26):12-3. PubMed ID: 11366489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary data on 141W94 reported.
    AIDS Patient Care STDS; 1998 Jan; 12(1):65-6. PubMed ID: 11361894
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.